Metastatic Breast Cancer

Use of genomics to guide treatment selection improved outcomes for certain patients with metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Elacestrant improved outcomes compared with standard endocrine therapy for certain women with pretreated ER-positive, HER2-negative metastatic breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer.

The FDA granted breakthrough therapy designation to trastuzumab deruxtecan for second-line treatment of patients with metastatic HER2-positive breast cancer.

DESTINY-Breast03 data presented at the virtual ESMO Congress showed that trastuzumab deruxtecan significantly improved PFS compared with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Patients with pretreated locally advanced or metastatic HER2-positive breast cancer had significantly longer PFS after treatment with [vic-]trastuzumab duocarmazine vs. physician’s choice of treatment, according to study results.

Genentech has decided to voluntarily withdraw its accelerated approval of atezolizumab plus nab-paclitaxel for treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer.

Trastuzumab deruxtecan significantly prolonged PFS compared with ado-trastuzumab emtansine among patients with HER2-positive metastatic breast cancer, topline data of a randomized phase 3 trial showed.

New research revealed that an algorithm for anemia detection using smartphone photos performed with 72.6% accuracy. It was the top story in hematology/oncology last week.

Total annual costs associated with metastatic breast cancer in the U.S. could exceed $152 billion in 2030, according to a study published in JNCI Cancer Spectrum.